File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Mifepristone: Contraceptive and non-contraceptive uses

TitleMifepristone: Contraceptive and non-contraceptive uses
Authors
Issue Date2002
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.co-obgyn.com
Citation
Current Opinion In Obstetrics And Gynecology, 2002, v. 14 n. 3, p. 325-330 How to Cite?
AbstractMifepristone is an orally active progesterone antagonist. It can be used for both contraceptive and non-contraceptive clinical indications. It is a very effective drug for emergency contraception with a low incidence of side effects. There is a potential for mifepristone to be used as a once-a-month pill. There is a need, however, for a simple, inexpensive and accurate method to identify the luteinizing hormone surge before this method can be used in clinical practice. The daily administration of mifepristone offers promise as an effective method of contraception but more studies need to be done. The combination of mifepristone with a prostaglandin analogue is a well-established method for termination of pregnancy of up to 9 weeks. Recent data suggest that this combination may also be used up to 9-13 weeks of pregnancy. Although mifepristone is effective in dilating the cervix before vacuum aspiration, misoprostol is probably the drug of choice in most situations. In the second trimester, mifepristone is effective in shortening the abortion process induced by prostaglandin analogues. The combination of mifepristone and prostaglandin also offers a medical method for management of miscarriages. Mifepristone has been used for a number of other indications, but further studies are needed before such treatment can be recommended. © 2002 Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/87225
ISSN
2015 Impact Factor: 2.134
2015 SCImago Journal Rankings: 0.905
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPak, CHen_HK
dc.contributor.authorNg, EHYen_HK
dc.contributor.authorOi, STen_HK
dc.date.accessioned2010-09-06T09:26:57Z-
dc.date.available2010-09-06T09:26:57Z-
dc.date.issued2002en_HK
dc.identifier.citationCurrent Opinion In Obstetrics And Gynecology, 2002, v. 14 n. 3, p. 325-330en_HK
dc.identifier.issn1040-872Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/87225-
dc.description.abstractMifepristone is an orally active progesterone antagonist. It can be used for both contraceptive and non-contraceptive clinical indications. It is a very effective drug for emergency contraception with a low incidence of side effects. There is a potential for mifepristone to be used as a once-a-month pill. There is a need, however, for a simple, inexpensive and accurate method to identify the luteinizing hormone surge before this method can be used in clinical practice. The daily administration of mifepristone offers promise as an effective method of contraception but more studies need to be done. The combination of mifepristone with a prostaglandin analogue is a well-established method for termination of pregnancy of up to 9 weeks. Recent data suggest that this combination may also be used up to 9-13 weeks of pregnancy. Although mifepristone is effective in dilating the cervix before vacuum aspiration, misoprostol is probably the drug of choice in most situations. In the second trimester, mifepristone is effective in shortening the abortion process induced by prostaglandin analogues. The combination of mifepristone and prostaglandin also offers a medical method for management of miscarriages. Mifepristone has been used for a number of other indications, but further studies are needed before such treatment can be recommended. © 2002 Lippincott Williams & Wilkins.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.co-obgyn.comen_HK
dc.relation.ispartofCurrent Opinion in Obstetrics and Gynecologyen_HK
dc.rightsCurrent Opinion in Obstetrics & Gynecology. Copyright © Lippincott Williams & Wilkins.en_HK
dc.titleMifepristone: Contraceptive and non-contraceptive usesen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1040-872X&volume=14&spage=325&epage=330&date=2002&atitle=Mifepristone:+contraceptive+and+non-contraceptive+usesen_HK
dc.identifier.emailPak, CH:pcho@hku.hken_HK
dc.identifier.emailNg, EHY:nghye@hkucc.hku.hken_HK
dc.identifier.authorityPak, CH=rp00325en_HK
dc.identifier.authorityNg, EHY=rp00426en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/00001703-200206000-00013en_HK
dc.identifier.pmid12032390-
dc.identifier.scopuseid_2-s2.0-0036262524en_HK
dc.identifier.hkuros66987en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036262524&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue3en_HK
dc.identifier.spage325en_HK
dc.identifier.epage330en_HK
dc.identifier.isiWOS:000175899000013-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridPak, CH=7402211440en_HK
dc.identifier.scopusauthoridNg, EHY=35238184300en_HK
dc.identifier.scopusauthoridOi, ST=7103241843en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats